Europe Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 CELL SOURCE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET APPLICATION COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 52
5 EUROPE MEDICAL CARTS MARKET: REGULATIONS 54
5.1 REGULATION IN U.S. 54
5.2 REGULATION IN CANADA 55
5.3 REGULATION IN EUROPE 55
5.4 REGULATION IN INDIA 55
5.5 REGUALTION IN JAPAN 56
6 MARKET OVERVIEW 58
6.1 DRIVERS 60
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS 60
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS 60
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES 61
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY 63
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT 64
6.2 RESTRAINT 65
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS 65
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 65
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS 66
6.3 OPPORTUNITIES 66
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS 66
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE 67
6.3.3 SURGE IN HEALTHCARE EXPENDITURE 67
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 68
6.4 CHALLENGES 69
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE 69
6.4.2 LACK OF SKILLED PROFESSIONALS 69
6.4.3 STRINGENT REGULATORY FRAMEWORK 69
7 IMPACT OF COVID-19 ON THE EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 71
7.1 IMPACT ON PRICE 71
7.2 IMPACT ON DEMAND 71
7.3 IMPACT ON SUPPLY CHAIN 72
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 72
7.5 CONCLUSION 73
8 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 74
8.1 OVERVIEW 75
8.2 SKIN CELLS 77
8.2.1 FIBROBLAST 78
8.2.2 KERATINOCYTES 78
8.2.3 ADIPOSE DERIVED STEM CELLS 79
8.2.4 HEPATOCYTES 79
8.2.5 MELANOCYTES 79
8.2.6 NEURAL STEM CELLS 79
8.2.7 OTHERS 79
8.3 BLOOD CELLS 79
8.3.1 PERIPHERAL BLOOD 80
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 80
8.3.3 CORD BLOOD STEM CELLS 80
8.3.4 OTHERS 80
9 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE 81
9.1 OVERVIEW 82
9.2 HUMAN IPSCS 85
9.3 MOUSE IPSCS 85
10 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT 87
10.1 OVERVIEW 88
10.2 CONSUMABLES & KITS 91
10.2.1 REPROGRAMMING KITS 92
10.2.2 MEDIA 92
10.2.3 TRANSFECTION KITS 92
10.2.4 CELL IDENTIFICATION KITS 92
10.2.5 ACCESSORIES 92
10.2.6 OTHERS 92
10.3 SERVICES 92
10.4 INSTRUMENTS 93
10.4.1 IMAGING SYSTEMS 94
10.4.2 ELECTROPORATION DEVICE 94
10.4.3 INCUBATORS 94
10.4.4 OTHERS 94
11 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 95
11.1 OVERVIEW 96
11.2 DRUG DISCOVERY AND DEVELOPMENT 99
11.3 ACADEMIC RESEARCH 99
11.4 DISEASE MODELLING 100
11.5 CELLULAR THERAPY 101
11.6 REGENERATIVE MEDICINE 101
11.7 TOXICOLOGY SCREENING 102
11.8 STEM CELL BANKING 103
11.9 3D BIOPRINTING 103
11.10 OTHERS 104
12 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER 105
12.1 OVERVIEW 106
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 109
12.3 RESEARCH LABORATORIES 109
12.4 DIAGNOSTIC LABORATORIES 110
12.5 OTHERS 111
13 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 112
13.1 OVERVIEW 113
13.2 DIRECT TENDER 115
13.3 RETAIL SALES 116
14 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION 117
14.1 EUROPE 118
14.1.1 GERMANY 125
14.1.2 FRANCE 128
14.1.3 U.K. 131
14.1.4 ITALY 134
14.1.5 RUSSIA 137
14.1.6 SPAIN 140
14.1.7 TURKEY 143
14.1.8 NETHERLANDS 146
14.1.9 SWITZERLAND 149
14.1.10 BELGIUM 152
14.1.11 REST OF EUROPE 155
15 EUROPE INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 156
15.1 COMPANY SHARE ANALYSIS: EUROPE 156
16 SWOT ANALYSIS 157
17 COMPANY PROFILE 158
17.1 FUJIFILM CORPORATION 158
17.1.1 COMPANY SNAPSHOT 158
17.1.2 REVENUE ANALYSIS 158
17.1.3 COMPANY SHARE ANALYSIS 159
17.1.4 PRODUCT PORTFOLIO 159
17.1.5 RECENT DEVELOPMENT 160
17.1.5.1 ACQUISITION 160
17.2 THERMO FISHER SCIENTIFIC INC. 161
17.2.1 COMPANY SNAPSHOT 161
17.2.2 REVENUE ANALYSIS 161
17.2.3 COMPANY SHARE ANALYSIS 162
17.2.4 PRODUCT PORTFOLIO 162
17.2.5 RECENT DEVELOPMENTS 165
17.2.5.1 EVENT 165
17.2.5.2 ACQUISITION 166
17.3 LONZA. 167
17.3.1 COMPANY SNAPSHOT 167
17.3.2 REVENUE ANALYSIS 167
17.3.3 COMPANY SHARE ANALYSIS 168
17.3.4 PRODUCT PORTFOLIO 168
17.3.5 RECENT DEVELOPMENTS 169
17.3.5.1 EXPANSION 169
17.4 MERCK KGAA 170
17.4.1 COMPANY SNAPSHOT 170
17.4.2 REVENUE ANALYSIS 170
17.4.3 COMPANY SHARE ANALYSIS 171
17.4.4 PRODUCT PORTFOLIO 171
17.4.5 RECENT DEVELOPMENT 174
17.4.5.1 AGREEMENT 174
17.5 EVOTEC SE. 175
17.5.1 COMPANY SNAPSHOT 175
17.5.2 REVENUE ANALYSIS 175
17.5.3 COMPANY SHARE ANALYSIS 176
17.5.4 PRODUCT PORTFOLIO 176
17.5.5 RECENT DEVELOPMENTS 176
17.5.5.1 AGREEMENT 176
17.5.5.2 COLLABORATION 177
17.6 APPLIED STEMCELL. 178
17.6.1 COMPANY SNAPSHOT 178
17.6.2 PRODUCT PORTFOLIO 178
17.6.3 RECENT DEVELOPMENTS 184
17.6.3.1 PRODUCT LAUNCH 184
17.7 AXOL BIOSCIENCE LTD. 185
17.7.1 COMPANY SNAPSHOT 185
17.7.2 PRODUCT PORTFOLIO 185
17.7.3 RECENT DEVELOPMENTS 188
17.7.3.1 MERGER 188
17.7.3.2 PRODUCT LAUNCH 189
17.8 CELL APPLICATIONS, INC. 190
17.8.1 COMPANY SNAPSHOT 190
17.8.2 PRODUCT PORTFOLIO 190
17.8.3 RECENT DEVELOPMENT 191
17.8.3.1 PARTNERSHIP 191

17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 192
17.9.1 COMPANY SNAPSHOT 192
17.9.2 REVENUE ANALYSIS 192
17.9.3 PRODUCT PORTFOLIO 193
17.9.4 RECENT DEVELOPMENT 193
17.9.4.1 ACQUISITION 193
17.10 CITIUS PHARMACEUTICALS, INC. 194
17.10.1 COMPANY SNAPSHOT 194
17.10.2 PRODUCT PORTFOLIO 194
17.10.3 RECENT DEVELOPMENT 194
17.10.3.1 AGREEMENT 194
17.11 CORNING INCORPORATED 195
17.11.1 COMPANY SNAPSHOT 195
17.11.2 REVENUE ANALYSIS 195
17.11.3 PRODUCT PORTFOLIO 196
17.11.4 RECENT DEVELOPMENT 196
17.11.4.1 AGREEMENT 196
17.12 FATE THERAPEUTICS 197
17.12.1 COMPANY SNAPSHOT 197
17.12.2 PRODUCT PORTFOLIO 197
17.12.3 RECENT DEVELOPMENT 197
17.12.3.1 CLINICAL TRIAL 197
17.13 GENECOPOEIA, INC. 198
17.13.1 COMPANY SNAPSHOT 198
17.13.2 PRODUCT PORTFOLIO 198
17.13.3 RECENT DEVELOPMENT 198
17.14 HOPSTEM BIOTECHNOLOGY LLC. 199
17.14.1 COMPANY SNAPSHOT 199
17.14.2 PRODUCT PORTFOLIO 199
17.14.3 RECENT DEVELOPMENT 199
17.14.3.1 PARTNERSHIP 199
17.15 HORIZON DISCOVERY LTD. 200
17.15.1 COMPANY SNAPSHOT 200
17.15.2 PRODUCT PORTFOLIO 200
17.15.3 RECENT DEVELOPMENT 200
17.16 LUMACYTE 201
17.16.1 COMPANY SNAPSHOT 201
17.16.2 PRODUCT PORTFOLIO 201
17.16.3 RECENT DEVELOPMENT 202
17.16.3.1 COLLABORATION 202
17.17 R & D SYSTEMS, INC. 203
17.17.1 COMPANY SNAPSHOT 203
17.17.2 REVENUE ANALYSIS 203
17.17.3 PRODUCT PORTFOLIO 204
17.17.4 RECENT DEVELOPMENT 205
17.18 REPROCELL INC. 206
17.18.1 COMPANY SNAPSHOT 206
17.18.2 PRODUCT PORTFOLIO 206
17.18.3 RECENT DEVELOPMENTS 207
17.18.3.1 COLLABORATION 207
17.18.3.2 FACILITY EXPANSION 208
17.18.3.3 SERVICE LAUNCH 208
17.19 TAKARA BIO INC. 209
17.19.1 COMPANY SNAPSHOT 209
17.19.2 REVENUE ANALYSIS 209
17.19.3 PRODUCT PORTFOLIO 210
17.19.4 RECENT DEVELOPMENTS 210
17.19.4.1 NEW FACILITY LAUNCH 210
17.20 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY) 211
17.20.1 COMPANY SNAPSHOT 211
17.20.2 REVENUE ANALYSIS 211
17.20.3 PRODUCT PORTFOLIO 212
17.20.4 RECENT DEVELOPMENT 212
17.20.4.1 ACQUISITION 212
18 QUESTIONNAIRE 213
19 RELATED REPORTS 217